Want to join the conversation?
$BDX 3Q15 PR: “We are pleased with our performance this quarter, which includes the results of CareFusion, and marks a historic milestone for BD. We are progressing well with the integration of CareFusion, and are on track to achieve the accretion targets we communicated for fiscal 2015 and 2016," said Vincent Forlenza, Chairman, CEO and President.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.